Literature DB >> 10531409

Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism.

D Cussac1, A Newman-Tancredi, V Pasteau, M J Millan.   

Abstract

The mitogen-activated protein kinase (MAPK) cascade is stimulated by both receptor tyrosine kinases and G protein-coupled receptors. We show that recombinant human dopamine D(3) receptors expressed in Chinese hamster ovary cells transiently activate MAPK via pertussis toxin-sensitive Gi and/or Go proteins. The involvement of D(3) receptors was confirmed by use of the D(3) agonists PD 128,907 and (+)-7-hydroxy-2-dipropylaminotetralin, which mimicked the response to dopamine (DA). Furthermore, haloperidol and the selective D(3) receptor antagonists S 14297 and GR 218,231 attenuated DA-induced MAPK activation; however, when tested alone, S 14297 weakly stimulated MAPK activity, suggesting partial agonist activity. The transduction mechanisms by which hD(3) receptors activate MAPK were explored with specific kinase inhibitors. Genistein and lavendustin A, inhibitors of tyrosine kinase activity, did not reduce DA-induced MAPK activation. In contrast, PD 98059, an inhibitor of MAPK kinase, and Ro 31-8220 and Gö 6983, inhibitors of protein kinase C (PKC), blocked DA-induced MAPK activation. However, MAPK activation was insensitive to PKC down-regulation by phorbol esters, indicating the involvement of an "atypical" PKC. Furthermore, MAPK activation involved phosphatidylinositol 3-kinase inasmuch as its inhibition by LY 294002 and wortmannin reduced DA-induced MAPK activation. In conclusion, this study demonstrates that stimulation of hD(3) receptors activates MAPK. This action is mediated via an atypical isoform of PKC, possibly involving cross-talk with products of phosphatidylinositol 3-kinase activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531409     DOI: 10.1124/mol.56.5.1025

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model.

Authors:  Ying Li; Eldo V Kuzhikandathil
Journal:  Brain Struct Funct       Date:  2012-01-29       Impact factor: 3.270

3.  Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.

Authors:  Mark J Millan; Loretta Iob; Jean-Louis Péglion; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2006-09-19       Impact factor: 4.530

4.  Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.

Authors:  Eldo V Kuzhikandathil; Samantha Cote; Soumava Santra; Aloke K Dutta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-20       Impact factor: 3.000

5.  Dopamine D2 Receptor-Mediated Modulation of Rat Retinal Ganglion Cell Excitability.

Authors:  Ning Yin; Yu-Long Yang; Shuo Cheng; Hong-Ning Wang; Xin Hu; Yanying Miao; Fang Li; Zhongfeng Wang
Journal:  Neurosci Bull       Date:  2019-10-12       Impact factor: 5.203

Review 6.  Role of dopamine receptors in ADHD: a systematic meta-analysis.

Authors:  Jing Wu; Haifan Xiao; Hongjuan Sun; Li Zou; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

7.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

8.  Identification and characterization of a novel class of atypical dopamine receptor agonists.

Authors:  E V Kuzhikandathil; S Kortagere
Journal:  Pharm Res       Date:  2012-05-01       Impact factor: 4.200

9.  Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells.

Authors:  Darren J Powell; Sophie Turban; Alexander Gray; Eric Hajduch; Harinder S Hundal
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

10.  Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII.

Authors:  Xian-Yu Liu; Li-Min Mao; Guo-Chi Zhang; Christopher J Papasian; Eugene E Fibuch; Hong-Xiang Lan; Hui-Fang Zhou; Ming Xu; John Q Wang
Journal:  Neuron       Date:  2009-02-12       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.